Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

Amanda D. Rice, Mathew M. Adams, Greg Wallace, Andrew M. Burrage, Scott F. Lindsey, Andrew J. Smith, Daniele Swetnam, Brandi R. Manning, Stacey A. Gray, Bernhard Lampert, Scott Foster, Randall Lanier, Alice Robertson, George Painter, Richard W. Moyer

Research output: Contribution to journalReview article

Abstract

CMX001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol to cidofovir (CDV), is being developed as a treatment for smallpox. In the absence of human cases of smallpox, new treatments must be tested for efficacy in animal models. Previously, we demonstrated the efficacy of CMX001 in protecting New Zealand White rabbits from mortality following intradermal infection with rabbitpox virus as a model for smallpox, monkeypox and for treatment of adverse reactions to smallpox vaccination. Here we extend these studies by exploring different dosing regimens and performing randomized, blinded, placebo-controlled studies. In addition, because rabbitpox virus can be transmitted via naturally generated aerosols (animal to animal transmission), we report on studies to test the efficacy of CMX001 in protecting rabbits from lethal rabbitpox virus disease when infection occurs by animal to animal transmission. In all cases, CMX001 treatment was initiated at the onset of observable lesions in the ears to model the use of CMX001 as a treatment for symptomatic smallpox. The results demonstrate that CMX001 is an effective treatment for symptomatic rabbitpox virus infection. The rabbitpox model has key similarities to human smallpox including an incubation period, generalized systemic disease, the occurrence of lesions which may be used as a trigger for initiating therapy, and natural animal to animal spread, making it an appropriate model.

Original languageEnglish (US)
Pages (from-to)47-62
Number of pages16
JournalViruses
Volume3
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Keywords

  • Antiviral
  • CMX001
  • Poxvirus
  • Rabbitpox
  • Smallpox treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans'. Together they form a unique fingerprint.

  • Cite this

    Rice, A. D., Adams, M. M., Wallace, G., Burrage, A. M., Lindsey, S. F., Smith, A. J., Swetnam, D., Manning, B. R., Gray, S. A., Lampert, B., Foster, S., Lanier, R., Robertson, A., Painter, G., & Moyer, R. W. (2011). Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses, 3(1), 47-62. https://doi.org/10.3390/v3010047